The 21st John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease
13th-14th March 2026
The John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease was held at the Royal Society, London, UK.
Those of you who attended this year will be able to revisit the presentations using the links below (your password will be emailed to you). We hope you enjoy.
Chris Thiemermann - Welcome
Hugh Montgomery - Final Frame: New concepts in end-of-life care
Ardeschir Ghofrani - Current challenges in emerging solutions in PH research
Athénaïs Boucly - New ways of patient stratification in PH: The plasma proteome
Martin Wilkins - Diagnostic microRNA signatures to support classification of PH
Vallerie McLaughlin - Puffs, pills and pumps: Role of prostacyclins in 2026
Michele D'Alto - New imaging guidelines as a part of risk assessment and treatment algorithms in PH
Lucie Clapp - Novel mechanisms underlying the therapeutic effects of prostacyclins
Vincent Cottin - Treating PH with interstitial lung disease
Jürgen Behr - Treatment of PH with pulmonary fibrosis
Marc Peters-Golden - Mechanism of the anti-fibrotic effects of prostaglandins
James May - Clinical and mechanistic insights into the therapeutic application of treprostinil in the treatment of pulmonary fibrosis
Jason Weatherald - Pulmonary vascular recruitment during exercise: A potential therapeutic endpoint in PAH and COPD
Jim White - Remote measurements of efficacy in PH: a step towards decentralized clinical trials?
Gabor Kovacs - Treatment options for early PH
Vijay Balasubramanian - Understanding the EXPEDITE study and its applicability in the current world
Olivier Sitbon - Tyrosine kinase inhibitors and PAH: A double-edged sword?
Vallerie McLaughlin and Jason Weatherald - Debate: Clinical trial design
